Celldex Therapeutics (NASDAQ:CLDX) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $64.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 102.21% from the stock’s current price.

Several other research analysts have also commented on the company. Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. Wells Fargo & Company raised their price objective on Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. UBS Group raised their price objective on Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Finally, Cantor Fitzgerald raised their price objective on Celldex Therapeutics from $61.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $61.92.

Celldex Therapeutics Stock Performance

Shares of CLDX traded down $0.53 during trading hours on Friday, hitting $31.65. The stock had a trading volume of 2,404,662 shares, compared to its average volume of 1,064,734. The firm has a market cap of $2.49 billion, a P/E ratio of -7.28 and a beta of 0.90. The company’s fifty day simple moving average is $38.45 and its 200 day simple moving average is $34.91. Celldex Therapeutics has a 12-month low of $22.10 and a 12-month high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.12. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.74 million. As a group, sell-side analysts predict that Celldex Therapeutics will post -4.17 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Large investors have recently modified their holdings of the business. Wellington Management Group LLP grew its stake in shares of Celldex Therapeutics by 11.5% during the second quarter. Wellington Management Group LLP now owns 9,543,671 shares of the biopharmaceutical company’s stock valued at $355,120,000 after acquiring an additional 983,195 shares in the last quarter. Commodore Capital LP grew its stake in shares of Celldex Therapeutics by 5.1% during the first quarter. Commodore Capital LP now owns 2,696,616 shares of the biopharmaceutical company’s stock valued at $85,537,000 after acquiring an additional 131,616 shares in the last quarter. Eversept Partners LP grew its stake in shares of Celldex Therapeutics by 24.6% during the first quarter. Eversept Partners LP now owns 1,788,016 shares of the biopharmaceutical company’s stock valued at $56,716,000 after acquiring an additional 353,291 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Celldex Therapeutics by 62.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,059,534 shares of the biopharmaceutical company’s stock valued at $33,596,000 after acquiring an additional 407,818 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in shares of Celldex Therapeutics by 438.3% during the second quarter. Assenagon Asset Management S.A. now owns 788,696 shares of the biopharmaceutical company’s stock valued at $29,347,000 after acquiring an additional 642,171 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.